Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Progression of DLBCL is the major obstacle for the success of chimeric antigen receptor-T
cell (CAR-T) with approximately 60% of the patients relapsing in the first year, and 40%
within 3 months, after infusion. While patient with DLBCL in Partial Response/Complete
Response at lymphodepletion have a 1-year Progression Free Survival (PFS) of 60-80%, those
with Stable Disease/Progressive Disease at time of lymphodepletion have a dismal PFS of
20-30%.
Trials showed that better expansion of CAR-T cells, even in patients with a progressive
disease, may overcome this grave prognosis and may result in better PFS